Lv1
28 积分 2023-12-27 加入
HER‐2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy
2天前
已完结
Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study
3天前
已完结
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial
7天前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
7天前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
7天前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
8天前
已完结
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
24天前
已完结
Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2–Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial
27天前
已完结
Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
1个月前
已完结
Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials
1个月前
已完结
皖公网安备34019202002308
